TY - JOUR
T1 - Glucagon underutilized among type 1 diabetes mellitus patients in Japan
AU - Murata, Takashi
AU - Okazaki, Kentaro
AU - Yanagisawa, Katsuyuki
AU - Yamada, Kenichi
AU - Kuribayashi, Nobuichi
AU - Totsuka, Yasuo
AU - Hiyoshi, Toru
AU - Naka, Motoji
AU - Sugimoto, Masatake
AU - Aoki, Yuji
AU - Waki, Masako
AU - Furuya, Miyuki
AU - Kitaoka, Haruko
AU - Oishi, Mariko
AU - Shimizu, Ikki
AU - Miyaoka, Hiroaki
AU - Yamamoto, Toshikazu
AU - Yamada, Kazunori
AU - Sakane, Naoki
PY - 2013/9/1
Y1 - 2013/9/1
N2 - Aim: Glucagon is recommended to treat severe hypoglycemia in nonhospital environments, when a patient with type 1 diabetes mellitus (T1DM) is unconscious and unable to eat or drink. However, the actual possession rate of glucagon in Japan has not been investigated. Subjects and Methods: We recruited 208 T1DM patients older than 15 years of age. The patients were treated at 16 hospitals and clinics in different regions of Japan. Answers were obtained using a self-Administered questionnaire about the possession, the experience of usage, and the preference to possess glucagon after reading what is glucagon and when it is used. A stepwise logistic regression analysis was performed to assess the influence of various factors on the possession of glucagon. Results: The possession rate of glucagon was 15.9%, and the rate of those who had experience of using glucagon to treat severe hypoglycemia was 6.0%. The rate of preference to possess glucagon at home after reading the description of glucagon was 39.0%. The possession of glucagon was significantly associated with results of the Glucagon Knowledge Test (odds ratio=24.1; 95% confidence interval, 3.2-183.3; P=0.002) and the history of severe hypoglycemia within 1 year (odds ratio=4.8; 95% confidence interval, 2.0-12.0; P=0.001). Conclusions: Glucagon as a measure to treat severe hypoglycemia was underutilized among T1DM patients in Japan.
AB - Aim: Glucagon is recommended to treat severe hypoglycemia in nonhospital environments, when a patient with type 1 diabetes mellitus (T1DM) is unconscious and unable to eat or drink. However, the actual possession rate of glucagon in Japan has not been investigated. Subjects and Methods: We recruited 208 T1DM patients older than 15 years of age. The patients were treated at 16 hospitals and clinics in different regions of Japan. Answers were obtained using a self-Administered questionnaire about the possession, the experience of usage, and the preference to possess glucagon after reading what is glucagon and when it is used. A stepwise logistic regression analysis was performed to assess the influence of various factors on the possession of glucagon. Results: The possession rate of glucagon was 15.9%, and the rate of those who had experience of using glucagon to treat severe hypoglycemia was 6.0%. The rate of preference to possess glucagon at home after reading the description of glucagon was 39.0%. The possession of glucagon was significantly associated with results of the Glucagon Knowledge Test (odds ratio=24.1; 95% confidence interval, 3.2-183.3; P=0.002) and the history of severe hypoglycemia within 1 year (odds ratio=4.8; 95% confidence interval, 2.0-12.0; P=0.001). Conclusions: Glucagon as a measure to treat severe hypoglycemia was underutilized among T1DM patients in Japan.
UR - http://www.scopus.com/inward/record.url?scp=84883362203&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84883362203&partnerID=8YFLogxK
U2 - 10.1089/dia.2012.0290
DO - 10.1089/dia.2012.0290
M3 - Article
C2 - 23758283
AN - SCOPUS:84883362203
SN - 1520-9156
VL - 15
SP - 748
EP - 750
JO - Diabetes Technology and Therapeutics
JF - Diabetes Technology and Therapeutics
IS - 9
ER -